Over 100 Mn Cartridges of rh-Insulin Supplied to Health Ministry;
345,000+ patients served
Bengaluru, Karnataka, India and Johor, Malaysia: June 30, 2025
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company, today announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the milestone of supplying 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s Ministry of Health (MoH). This achievement reinforces Biocon Biologics’ long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country.
Since entering the Malaysian market in 2016, Biocon Biologics has played a pivotal role in transforming diabetes management, and has supplied over 100 million cartridges of rh-insulin serving over 345,000 patients. Biocon Biologics’ public-private partnership with the Malaysian government exemplifies a successful model for building a resilient biotech ecosystem by driving innovation, developing local talent, enabling better patient outcomes and advancing insulin self-sufficiency in Malaysia.
Susheel Umesh, Chief Commercial Officer, Biocon Biologics, said: “Expanding access to over 345,000 diabetes patients in Malaysia by providing over 100 million cartridges of rh-insulin reinforces our commitment to equitable diabetes care. Every cartridge we produce at our state-of-the-art facility in Johor is a lifeline for someone living with diabetes. Our partnership with the Malaysian Ministry of Health and Duopharma underlines how local manufacturing and global expertise can come together to create scalable, sustainable healthcare solutions for patients.”
Leonard Ariff Abdul Shatar, Group Managing Director, Duopharma Biotech Berhad, said: “This significant milestone truly underscores the strength of our enduring, multi-year partnership with Biocon Biologics, an impactful collaboration that aligns with Duopharma Biotech’s vision to ‘Provide Smarter Solutions for a Healthier Life’. Through our joint efforts, we are committed to elevating diabetes care across Malaysia, ensuring consistent access to affordable, high-quality insulin. We proudly support the Ministry of Health in strengthening national healthcare resilience, and improving the lives of Malaysians living with diabetes.”
Globally, Biocon Biologics is among the Top 3* players for rh-Insulin and Insulin Glargine. In collaboration with its commercial partner Duopharma Marketing Sdn. Bhd., a subsidiary of Malaysia’s leading pharmaceutical company Duopharma Biotech Berhad, Biocon Biologics has supported diabetes care across Malaysia since 2016.
Biocon Biologics has established a Center of Excellence (CoE) for insulins at its state-of-the-art manufacturing facility in Johor, Malaysia with a cumulative investment of USD 600 million since 2011. The facility is equipped with end-to-end capabilities to produce a broad portfolio of insulins — regular, basal and rapid — in multiple presentations including cartridges and delivery devices. The prestigious Malaysia Book of Records has recognized Biocon Sdn. Bhd., Malaysia as the first and largest integrated insulin manufacturer in Malaysia.
Biocon Biologics is committed to serve ‘1 in 5’ insulin-dependent people worldwide and has provided 9.2 billion doses of rh-Insulin and Insulin Glargine cumulatively to patients across the globe.
*Source and Disclaimer: Based on Biocon analysis for rh-Insulin and Insulin Glargine- MAT Q4 2024 (CY); The data presented hereunder inter alia volumes, projections, market share, is based solely on our study, interpretation and conclusion derived through analysis of different data sets from varied sources inter alia IQVIA.
About Biocon Biologics Limited:
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.
Biocon Biologics has commercialized nine biosimilars from its portfolio which are addressing patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goal (SDGs).
Website: www.bioconbiologics.com; Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates. For FY24 Integrated Annual Report of Biocon Biologics click here
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune.
Download Press Release
